Helmholtz Munich Builds 5-Target Obesity Drug, Beating Semaglutide and Tirzepatide in Mice
Updated
Updated · Earth.com · May 14
Helmholtz Munich Builds 5-Target Obesity Drug, Beating Semaglutide and Tirzepatide in Mice
3 articles · Updated · Earth.com · May 14
A single hybrid molecule from Helmholtz Munich beat semaglutide and a GLP-1/GIP comparator in obese mice over two weeks, cutting food intake, body fat, weight and fasting blood sugar more sharply.
The drug combines GLP-1 and GIP with lanifibranor-linked PPAR activity, delivering the cargo only to incretin-responsive cells and using about 6,898 times less lanifibranor than standalone dosing tied to liver effects.
Clamp tests showed stronger insulin sensitivity even when researchers matched body weight against the older drug, while blocking PPARδ erased the extra glucose-control benefit but not the weight loss.
Mice also showed less liver and muscle inflammation, lower liver fat and better heart pumping without drops in blood pressure; expected lanifibranor side effects such as fluid retention, anemia and weight gain did not appear.
The Nature study is still preclinical, but it marks the first in-vivo test of one molecule hitting GLP-1, GIP and three PPAR switches, pointing to a possible weekly shot for obesity, diabetes and fatty liver if human trials succeed.
A new drug promises to be an 'appetite brake' and 'metabolic engine.' But can it overcome the 90% failure rate from mouse to man?
Will a drug that acts as a 'metabolic engine' solve obesity, or just deepen our reliance on pharmaceuticals over lifestyle changes?